Based on this principle, and considering that our results indicated that Grp94 in complexes with IgG was the soluble form of the tumor antigen, we wanted to test the immune response in PBMCs of cancer patients challenged with Grp94, at both 10 and 100 ng/ml. This evidence concerns the gene HSP90B1 and cancer.